Canadian Gout Disease Treatment Market size stood at USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Approximately 681,000 (2.4%) Canadians aged 20 years and older have been diagnosed with gout and other crystal arthropathies, and 54,000 (1.9 per 1,000 persons per year) were newly diagnosed in 2016–2017. The prevalence and incidence of diagnosed gout and other crystal arthropathies generally increase with age. They are higher among males (3.7% and 2.8 per 1,000 persons per year) than females (1.1% and 1.0 per 1,000 persons per year). The factors such as government initiatives and support, rising demand for advanced treatment, and growing market players offering newer products are likely to drive the market.
The development of gout and other crystal arthropathies can be attributed to many factors, including obesity, diet, alcohol intake, and certain medications. Gout and other crystal arthropathies can be managed with medication and lifestyle changes. Furthermore, growing research and development activities focusing on innovation and development of gout therapeutic agents and growing awareness associated with gout treatment are further stimulating the industry growth. There are many clinical trials in the process. Many new products are expected to be launched in the coming few years, propelling the industry growth during the forecast period.